Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures, which might be useful in the treatment of cancers, and vascular and metabolic diseases; and LB-200 series for the treatment of chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; pharmacologic study with the National Cancer Institute; and clinical research support agreement with City of Hope National Medical Center to carry out a Phase 1b clinical trial of its LB-100, a protein phosphatase inhibitor for small cell lung cancer. The company was incorporated in 2005 and is based in East Setauket, New York.
IPO Year:
Exchange: NASDAQ
Website: lixte.com
| Date | Price Target | Rating | Analyst |
|---|
Pre-Clinical Study in Collaboration with Netherlands Cancer Instituteis in addition to LIXTE's Ongoing Clinical Trials for Ovarian and Colorectal Cancers PASADENA, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical company, today announced it will conduct a new pre-clinical study in collaboration with Netherlands Cancer Institute (NKI) to test whether "initiated" cells that carry mutations found in cancer cells can be eliminated by treatment with LIXTE's proprietary compound LB-100. "In addition to our ongoing clinical trials in ovarian and colorectal cancer, this study represents a new o
-Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal Cancer- -Received Exclusive Patent License Agreement with the NIH on LB-100's Potential in Enhancing Cancer Immunotherapies- -Two Breakthrough Publications in Medical Journals, EMBO and Cancer Discovery,Supporting LIXTE's Clinical Trial Program- PASADENA, Calif, March 27, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on its recent activities. "C
-- As Published in Two Scientific Journals, Findings Open Potential Biomarker Strategy for Patient Response to LB-100 -- PASADENA, CALIF., March 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company, today announced online publication of new pre-clinical data in BioXriv and International Journal of Pharmaceutics demonstrating how the Company's lead clinical compound, LB-100, is converted into its active form, endothall, a protein phosphatase (PP2A) inhibitor that has been found to be effective in cancer treatment in combination with immunotherapy. As published in BioXriv, scientists at the Netherl
-- Lurie Cancer Center Completes Dosing of First Patient with LIXTE's LB-100 in Combination with GSK's Immunotherapy Dostarlimab -- PASADENA, CALIF., Feb. 25, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical company, today announced it has added the Robert H. Lurie Comprehensive Cancer Center (Lurie Cancer Center) of Northwestern University as a second site in a clinical trial combining the Company's proprietary compound LB-100 with GSK's Dostarlimab to treat ovarian clear cell cancer. Emily M. Hinchcliff, MD, MPH, will lead the clinical trial at Lurie Cancer Center, a renown Chicago-based National Canc
PASADENA, CALIF., Feb. 13, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical company, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 434,784 shares of the Company's common stock at a purchase price of $2.415 per share. In addition, in a concurrent private placement, the Company issued unregistered warrants to purchase up to an aggregate of 434,784 shares of common stock. The warrants have an exercise price of $2.29 per share and are exercisable for five years from the date of issuance. H
PASADENA, CALIF., Feb. 11, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical company, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 434,784 shares of its common stock at a purchase price of $2.415 per share, in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to an aggregate of 434,784 shares of common stock. The warrants will have an exercise price of $2.29 per share and will be exercisable for five years from the date
PASADENA, CALIF., Feb. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical company, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission (the "SEC") of the Company's Registration Statement on Form S-1 (No. 333-282781), as amended, originally filed on October 23, 2024 (the "Registration Statement"), as the Company no longer intends to pursue a public offering under the Registration Statement at this time. The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the R
Patent Covers Combining LIXTE's LB-100 with Various Innovative Cancer Immunotherapies PASADENA, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) ("LIXTE" or the "Company") today announced it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent application number 16/467,721, titled, "Oxabicycloheptanes for Modulation of Immune Response," for combining the Company's LB-100 compound with various innovative cancer immunotherapies. "The patent award further bolsters LIXTE's existing intellectual property portfolio and underscores the Company's commitment to pioneering research and delivering in
PASADENA, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) ("LIXTE" or the "Company"), today announced the dosing of the first patient in a new clinical trial in collaboration with the Netherlands Cancer Institute (NKI) and supported by F. Hoffmann-La Roche Ltd. ("Roche") for treatment of unresponsive (MSI Low) metastatic colorectal cancer. As part of the clinical trial (NCT06012734, clinicaltrials.gov), LIXTE is providing its lead compound, LB-100, and Roche is providing atezolizumab (Tecentriq ®, a PDL1 inhibitor) through the imCORE Network, a global academic-industry partnership that aims to accelerate cancer immunotherapy research through inst
-Collaboration with NKI and Funding Support for New Colorectal Cancer Clinical Trial by Major Pharma Company- -Distinguished Oncologist Jan Schellens Joins LIXTE as Chief Medical Officer- -Preclinical Data Published in Journal EMBO Reports Shows LB-100 as Potentially Enhancing the Benefit of Immunotherapy- -LIXTE to Present at Two Upcoming Investor Conferences- PASADENA, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on the Company's recent activities. "We are
SC 13G - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)
SC 13G/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)
SC 13G - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)
8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
10-Q - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
424B4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
EFFECT - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
S-1/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
S-1 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
10-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)
4/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)
PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced the appointment of Jan Schellens, M.D., Ph.D., as Chief Medical Officer (CMO). Dr. Schellens brings to LIXTE more than 25 years of clinical experience as a medical oncologist, pharmacologist and clinical pharmacologist, including more than two decades developing and bringing new drugs to market. He assumes the CMO role at LIXTE effective August 1, 2024, succeeding James S. Miser, M.D., who is leaving the Company after serv
Biotechnology Veteran Bas van der Baan Brings Precision Oncology Expertise; Founder John S. Kovach Named Executive Chairman PASADENA, CA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, announced that Bas van der Baan has been named as President and Chief Executive Officer of the Company, and as Vice Chairman of the Board of Directors, effective as of September 26, 2023. He has been a member of LIXTE'S Board of Directors since June 2022. Mr. van der Baan succeeds John S. Kovach, M.D., 87, who founded the Company in 2005 a
PASADENA, CA, June 21, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announced the appointment of Bas van der Baan to its Board of Directors. He will serve as an independent director. Dr. John S. Kovach, Founder and Chief Executive Officer of Lixte, commented, "We are very pleased to welcome Mr. van der Baan to our Board of Directors. Mr. van der Baan has over 20 years of experience in the biotechnology industry with a key focus on oncology and diagnostics. He has extensive knowhow in the journey from clinical development to reimbursement and commercialization
Bernards is internationally recognized for his contributions to the development of effective anti-cancer drugs from their earliest stages through clinical use PASADENA, CA, June 15, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announced the appointment of Professor René Bernards to its Board of Directors. Professor Bernards will serve as an independent director. Dr. John S. Kovach, Founder and Chief Executive Officer of Lixte, commented, "We are very pleased to welcome Professor Bernards to our Board of Directors and we look forward to his insight and
EAST SETAUKET, New York, April 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. ("Lixte" or the "Company") (NASDAQ:LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, announced the appointment of Gil N Schwartzberg to its Board of Directors. Mr. Schwartzberg is filling a vacancy created by the resignation of Winson (Sze Chun) Ho, M.D. Dr. John S. Kovach, the Founder and Chief Executive Officer of Lixte, commented, "Gil Schwartzberg has played an important role advising and supporting Lixte since its inception. We are pleased to be welcoming Mr. Schwartzberg to our Board of Directors." Dr. Kovach continue